Trial Profile
A Multicenter, Randomized, Double Blind, Placebo-controlled, Parallel Group, Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Abilify Tablet(Aripiprazole) as an Adjunctive Treatment in the Treatment of Major Depressive Episode Associated With Bipolar I or II Disorder
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 26 Oct 2021
Price :
$35
*
At a glance
- Drugs Aripiprazole (Primary)
- Indications Bipolar I disorders; Bipolar II disorders
- Focus Therapeutic Use
- Acronyms APOLLO
- Sponsors Korea Otsuka Pharmaceutical
- 22 Oct 2021 Planned End Date changed from 1 Jun 2020 to 1 Nov 2024.
- 22 Oct 2021 Planned primary completion date changed from 1 Mar 2020 to 1 Oct 2024.
- 04 Jan 2019 Planned End Date changed from 1 Feb 2022 to 1 Jun 2020.